Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

The drug perturbation map

Derived

All 92 clinical kinase inhibitors placed in pathway-perturbation space (Π_d = D · T · P), reduced to 2D by PCA. PC1: 95.1% var, PC2: 3.3% var. Color = stated primary target class; bubble size = norm of Π_d ("pharmacological loudness").

PC1 (95.1% var)PC2 (3.3% var)AbemaciclibAbrocitinibAcalabrutinibAfatinibAlectinibAlpelisibApatinibAsciminibAvapritinibAxitinibBaricitinibBinimetinibBosutinibBrigatinibCabozantinibCanertinibCapivasertibCapmatinibCeritinibCobimetinibCrizotinibDabrafenibDacomitinibDarovasertibDasatinibDefactinibDeucravacitinibDuvelisibEncorafenibEntrectinibErdafitinibErlotinibEverolimusFedratinibFostamatinibFutibatinibGedatolisibGefitinibGilteritinibIbrutinibIdelalisibImatinibInavolisibInfigratinibLapatinibLarotrectinibLazertinibLeniolisibLenvatinibLorlatinibMidostaurinMitapivatMobocertinibNeratinibNetarsudilNilotinibNintedanibOsimertinibPacritinibPalbociclibPaxalisibPazopanibPemigatinibPexidartinibPirtobrutinibPonatinibPralsetinibQuizartinibRabusertibRegorafenibRemibrutinibRepotrectinibRibociclibRipretinibRuxolitinibSelpercatinibSelumetinibSirolimusSorafenibSunitinibTemsirolimusTenalisibTepotinibTivozanibTofacitinibTrametinibTucatinibUmbralisibUpadacitinibVandetanibVemurafenibZanubrutinib

Click any drug for its full pathway shadow, Hallmark-of-Cancer radar, and anti-tumor matches.

Next steps

Find mechanistic duplicates → · Build rational combinations → · Overlay tumors on this same map →